Additional Volume Molnupiravir (EIDD-2801/MK-4482) Supply Agreement for Pandemic Purposes

Concepts

• pharmaceutical products
• first oral
• supply agreement
• additional volume molnupiravir
• additional procurement of molnupiravir
• units of molnupiravir
• pandemic purposes
• eidd-2801
• antiviral drugs
• regulatory approval

Location

United Kingdom:

Description

Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. This agreement is for the procurement of 1,750,000 units of Molnupiravir (EIDD-2801/MK-4482). It is one of the first oral and direct-acting antiviral drugs globally and the first to receive regulatory approval and is part of the UK’s multi-layered approach to COVID-19.

Total Quantity or Scope

Additional procurement of Molnupiravir (EIDD-2801/MK-4482).

Award Detail

Award Criteria

CPV Codes

• 33600000 - Pharmaceutical products

Legal Justification

Please see Contracts Finder Notice for full justification.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors and (iii) impact fair competition between vendors.